Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16467747rdf:typepubmed:Citationlld:pubmed
pubmed-article:16467747lifeskim:mentionsumls-concept:C0155626lld:lifeskim
pubmed-article:16467747lifeskim:mentionsumls-concept:C0443315lld:lifeskim
pubmed-article:16467747lifeskim:mentionsumls-concept:C0019134lld:lifeskim
pubmed-article:16467747lifeskim:mentionsumls-concept:C0206460lld:lifeskim
pubmed-article:16467747lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:16467747lifeskim:mentionsumls-concept:C0036043lld:lifeskim
pubmed-article:16467747lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:16467747lifeskim:mentionsumls-concept:C0520997lld:lifeskim
pubmed-article:16467747lifeskim:mentionsumls-concept:C0205251lld:lifeskim
pubmed-article:16467747pubmed:issue1lld:pubmed
pubmed-article:16467747pubmed:dateCreated2006-2-9lld:pubmed
pubmed-article:16467747pubmed:abstractTextIn ST-segment elevation myocardial infarction (STEMI) treated with fibrin-specific thrombolytic agents, early intravenous unfractionated heparin (UFH) is warranted. Low molecular weight heparin Enoxaparin currently represents an alternative to UFH, to be used until hospital discharge. Since optimal dosing of subcutaneous Enoxaparin is not standardized, we conducted an observational study to compare safety and efficacy of low (4,000 U once daily) vs full dose (100 U/kg twice daily) regimens.lld:pubmed
pubmed-article:16467747pubmed:languageenglld:pubmed
pubmed-article:16467747pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16467747pubmed:citationSubsetIMlld:pubmed
pubmed-article:16467747pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16467747pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16467747pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16467747pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16467747pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16467747pubmed:statusMEDLINElld:pubmed
pubmed-article:16467747pubmed:monthFeblld:pubmed
pubmed-article:16467747pubmed:issn0026-4725lld:pubmed
pubmed-article:16467747pubmed:authorpubmed-author:GattiCClld:pubmed
pubmed-article:16467747pubmed:authorpubmed-author:MarestaAAlld:pubmed
pubmed-article:16467747pubmed:authorpubmed-author:RubboliAAlld:pubmed
pubmed-article:16467747pubmed:authorpubmed-author:SpinoloLLlld:pubmed
pubmed-article:16467747pubmed:authorpubmed-author:ParolloRRlld:pubmed
pubmed-article:16467747pubmed:authorpubmed-author:SpitaliGGlld:pubmed
pubmed-article:16467747pubmed:issnTypePrintlld:pubmed
pubmed-article:16467747pubmed:volume54lld:pubmed
pubmed-article:16467747pubmed:ownerNLMlld:pubmed
pubmed-article:16467747pubmed:authorsCompleteYlld:pubmed
pubmed-article:16467747pubmed:pagination131-7lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:meshHeadingpubmed-meshheading:16467747...lld:pubmed
pubmed-article:16467747pubmed:year2006lld:pubmed
pubmed-article:16467747pubmed:articleTitleSubcutaneous enoxaparin following thrombolysis and intravenous unfractionated heparin in ST-elevation acute myocardial infarction: safety and efficacy of low vs full dose.lld:pubmed
pubmed-article:16467747pubmed:affiliationDivision of Cardiology, Ospedale Maggiore, Bologna, Italy. andrearubboli@libero.itlld:pubmed
pubmed-article:16467747pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16467747pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:16467747pubmed:publicationTypeMulticenter Studylld:pubmed